A possible explanation for not finding an association between a reduced BMD and a lower breast cancer recurrence risk might be that women with osteoporosis have less benefit of aromatase inhibitors because their oestrogen levels tend to be lower than in women with a normal BMD. This evidence concerns the gene CYP19A1 and breast cancer.